These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25649181)

  • 1. Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
    Noordam R; Direk N; Sitlani CM; Aarts N; Tiemeier H; Hofman A; Uitterlinden AG; Psaty BM; Stricker BH; Visser LE
    J Psychiatr Res; 2015 Mar; 62():31-7. PubMed ID: 25649181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HTR2A gene variation is involved in antidepressant treatment response.
    Lucae S; Ising M; Horstmann S; Baune BT; Arolt V; Müller-Myhsok B; Holsboer F; Domschke K
    Eur Neuropsychopharmacol; 2010 Jan; 20(1):65-8. PubMed ID: 19758789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine.
    Gassó P; Rodríguez N; Boloc D; Blázquez A; Torres T; Gortat A; Plana MT; Lafuente A; Mas S; Arnaiz JA; Lázaro L
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jul; 77():236-240. PubMed ID: 28456685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.
    Noordam R; Avery CL; Visser LE; Stricker BH
    Pharmacogenomics; 2016 Jun; 17(9):1029-40. PubMed ID: 27248517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.
    Breitenstein B; Scheuer S; Pfister H; Uhr M; Lucae S; Holsboer F; Ising M; Brückl TM
    CNS Spectr; 2014 Apr; 19(2):165-75. PubMed ID: 23880209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the
    Gassó P; Blázquez A; Rodríguez N; Boloc D; Torres T; Mas S; Lafuente A; Lázaro L
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):711-718. PubMed ID: 29975559
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.
    Breitenstein B; Scheuer S; Brückl TM; Meyer J; Ising M; Uhr M; Holsboer F
    J Psychiatr Res; 2016 Feb; 73():86-95. PubMed ID: 26704739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder.
    Lin E; Chen PS; Chang HH; Gean PW; Tsai HC; Yang YK; Lu RB
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1167-72. PubMed ID: 19560507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomewide interaction and enrichment analysis on antidepressant response.
    Antypa N; Drago A; Serretti A
    Psychol Med; 2014 Mar; 44(4):753-65. PubMed ID: 23809733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
    Fabbri C; Minarini A; Niitsu T; Serretti A
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1093-118. PubMed ID: 24930681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
    Kato M; Fukuda T; Wakeno M; Fukuda K; Okugawa G; Ikenaga Y; Yamashita M; Takekita Y; Nobuhara K; Azuma J; Kinoshita T
    Neuropsychobiology; 2006; 53(4):186-95. PubMed ID: 16874005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments.
    Serretti A; Benedetti F; Zanardi R; Smeraldi E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1074-84. PubMed ID: 15939518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
    Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
    Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
    Biernacka JM; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Baune BT; Kato M; Liu YL; Praphanphoj V; Stingl JC; Tsai SJ; Kubo M; Klein TE; Weinshilboum R
    Transl Psychiatry; 2015 Apr; 5(4):e553. PubMed ID: 25897834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.
    Noro M; Antonijevic I; Forray C; Kasper S; Kocabas NA; Lecrubier Y; Linotte S; Mendlewicz J; Montgomery S; Snyder L; Souery D; Verbanck P; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):228-31. PubMed ID: 20453658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression.
    Dubovsky SL
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):369-79. PubMed ID: 25554071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients.
    Perlis RH; Fijal B; Dharia S; Heinloth AN; Houston JP
    Biol Psychiatry; 2010 Jun; 67(11):1110-3. PubMed ID: 20110084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression.
    Baune BT; Dannlowski U; Domschke K; Janssen DG; Jordan MA; Ohrmann P; Bauer J; Biros E; Arolt V; Kugel H; Baxter AG; Suslow T
    Biol Psychiatry; 2010 Mar; 67(6):543-9. PubMed ID: 20044070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.